As part of its manufacturing sites modernization program, Binnopharm Group, a leading Russian pharmaceutical company, has launched a new suppository...
In 2023, the Medsintez Plant, in collaboration with the Promomed Group of Companies, launched the production of a full cycle of hypoglycemic drugs Enligria (liraglutide) and Quincenta (semaglutide) used in treating type II diabetes mellitus, including in patients with obesity and overweight or cardiovascular disease.
The product was developed as part of the state strategy for increasing the population's life expectancy and quality of life and improving medicine availability.
Ocugen, Inc., a biotechnology company focused on discovering, developing, and commercializing novel gene therapies, biologicals, and vaccines, May 23th...
Read more
Filtration and ventilation elements
CR-doors
Laminar flow devices
Furniture for cleanrooms
Panel construction, double-glazed windows
Pass-boxes
Read more
Read more
The review for the second quarter of 2024 provides information on the inspection of manufacturers of veterinary medicines for compliance with the requirements of the Good Manufacturing Practice (GMP).
This review provides information on the inspection of manufacturers of veterinary medicines for compliance with the requirements of the Good Manufacturing Practice (GMP) which is carried out by specialists of the Federal State Budgetary Institution "The All-Russian State Center for Quality and Standardization of Veterinary Drugs and Feed" (FSBI "VGNKI").
In January–June 2023, Russian manufacturers produced 342.5 billion rubles’ worth of ready-made pharmaceutical drugs (manufacturer’s prices, VAT included), down 2.6% from the same period in 2022.
In January–May 2023, Russian manufacturers produced 282 billion rubles’ of pharmaceutical drugs (manufacturer’s prices, VAT included), down 5.8% from the same period in 2022.
In January–March 2023, the online sales or reservations of pharmacy products (pharmaceutical drugs and parapharmaceuticals) in Russia were 80.2 billion rubles (end-user prices, VAT included), up 2.3% from January–March 2022 (against 69.6% in Q1 2022, with its rush demand).